To further assess combination DHODH and BCL-XL targeting as a therapeutic strategy for PDAC, we first evaluated for maximum tolerated doses of the combination of BQ and DT2216 in non-tumor bearing animal models. Here, BCL2L1 is linked to neoplasm.